Hypertension Caused by VEGF-Signaling Pathway Inhibitors

JHOP - December 2017 Vol 7, No 4 - Symptom Management Overview
Donald C. Moore, PharmD, BCPS, BCOP
Pharmacist Clinical Coordinator-Oncology
Levine Cancer Institute
Department of Pharmacy
Carolinas HealthCare System
Rock Hill, SC
Margaret M. Kientzel, PharmD
Oncology Staff Pharmacist
Levine Cancer Institute
Department of Pharmacy
Carolinas HealthCare System
Charlotte, NC
Adenike Fasan, BPharm
Pharmacist Clinical Coordinator-Oncology
Levine Cancer Institute
Department of Pharmacy
Carolinas HealthCare System
Charlotte, NC

Symptom Overview

Targeting and inhibiting the vascular endothelial growth factor (VEGF)-signaling pathway has become an integral modality in the treatment of a variety of malignancies, including renal-cell carcinoma (RCC); glioblastoma; hepatocellular carcinoma; gastrointestinal stromal tumors; and colorectal, lung, gastric, and ovarian cancers. Monoclonal antibodies and tyrosine kinase inhibitors (TKIs) that make up these types of drugs include bevacizumab, ramucirumab, cabozantinib, regorafenib, sorafenib, sunitinib, ponatinib, and axitinib. A classwide adverse event associated with the VEGF-signaling pathway inhibitors is cardiovascular toxicity, which can manifest as hypertension, thromboembolic disease, proteinuria, and heart failure.1

Hypertension is the most common cardiovascular event that may occur with VEGF-signaling pathway inhibitors.1 For example, the overall incidence of hypertension with bevacizumab has been described as being up to 24%, with up to 16% of patients experiencing grade 3 to 4 hypertension (Table 1).2-5 With sorafenib, all-grade hypertension may occur in 23.4% of patients, with 5.7% having severe, grade 3 to 4 hypertension.6 Although untreated hypertension can lead to severe medical events, such as myocardial infarction or stroke, some evidence suggests that hypertension secondary to anti–VEGF-signaling pathway therapy can be a biomarker for clinical efficacy of this class of drugs in the treatment of various malignancies.7

Table 1


VEGF represents a family of proteins that are involved in the regulation of vascular and lymphatic endothelium.1 VEGF binds to the tyrosine kinase receptors VEGFR1, VEGFR2, and VEGFR3, which comprise the VEGF-signaling pathway. The VEGF-signaling pathway is a critical component in the formation and maintenance of blood vessels, a process known as angiogenesis.8 In the context of cancer, angiogenesis is a factor in tumor growth and metastasis formation. When the VEGF-signaling pathway is inhibited in tumor cells, it can prevent tumor angiogenesis.

VEGF is highly expressed in endothelial cells.8 The activation of VEGF can lead to the phosphorylation of endothelial nitric oxide synthase, which increases the production of nitric oxide.7 Through this mechanism, VEGF plays a role in nitric oxide production and vasodilation. It has been proposed that when the VEGF-signaling pathway is inhibited, hypertension may occur secondary to the subsequent decrease in nitric oxide production.7 Another proposed mechanism by which VEGF-signaling pathway inhibition leads to hypertension is that inhibition of the VEGF-signaling pathway may increase the production of endothelin-1, a potent vasoconstrictor.1

Several risk factors have been identified that may predispose patients to VEGF-signaling pathway inhibitor–induced hypertension. Specifically, preexisting hypertension, obesity, and older age were predictive risk factors for VEGF-signaling pathway inhibitor–induced hypertension with the use of sorafenib, pazopa­nib, and sunitinib.7 In addition, the risk for hypertension may be associated with the tumor type being treated, as well as the dose of the VEGF inhibitor. It has been suggested that patients with RCC who receive high doses of bevacizumab may be at an increased risk for hypertension.2 In addition, patients who receive sunitinib or sorafenib for metastatic RCC have been shown to be at an increased risk for treatment-related hypertension compared with patients who receive these drugs for other indications.9

Treatment Options

Before the initiation of anti–VEGF-signaling pathway therapy, patients should be evaluated for preexisting hypertension and for risk factors for cardiovascular disease.10 For patients who have hypertension as a result of anti–VEGF-signaling pathway therapy, hypertension should be promptly managed to prevent further complications. An important reason to control blood pressure (BP) in this setting is that management of comorbidities has a demonstrated positive effect on survival in patients with cancer.11

Hypertension secondary to VEGF-signaling pathway inhibitors should be managed similarly to hypertension in the general population: there is no evidence to suggest otherwise. Although no formal guidelines exist for managing VEGF-signaling pathway inhibitor–induced hypertension, the National Cancer Institute (NCI) recommends following the Joint National Committee hypertension guidelines in this setting.12,13 Therefore, a common BP goal is <140/90 mm Hg. The NCI recommends monitoring BP weekly during the first cycle of anti–VEGF-signaling pathway therapy, and then at least every 2 to 3 weeks for the duration of treatment.12

In general, patients whose BPs increase to ≥140/90 mm Hg after initiation of anti–VEGF-signaling pathway therapy should initiate antihypertensive therapy, titrate any BP medication, or add another antihypertensive medication to the regimen if they are already receiving a BP-lowering medication without room to titrate.12 Although lifestyle modifications, such as diet, exercise, and weight loss, are often suggested for the general hypertensive population, these strategies may not be suitable for patients with cancer and hypertension secondary to anti–VEGF-signaling pathway therapy.14 Many of these patients may have unintentional weight loss or fatigue related to their cancer or its treatment, rendering lifestyle modifications difficult to implement. Aside from medical management, in cases of severe hypertension, some anti–VEGF-signaling pathway therapies may need to be temporarily interrupted until poorly controlled BP or hypertensive crises can be managed.12

Angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs) are 3 antihypertensive drug classes that should be considered for most patients who need to initiate therapy for hypertension secondary to anti–VEGF-signaling pathway therapy (Table 2).5,12,13 Thiazide diuretics and beta-blockers may also be considered. The superiority of one class of antihypertensive over another has not been demonstrated.12

Table 2

The choice of the antihypertensive drug in this setting should consider several patient-specific factors, including the potential for drug interactions, preexisting antihypertensive medications, and comorbidities. For example, as was demonstrated in a retrospective study, patients with RCC whose VEGF-signaling pathway inhibitor–induced hypertension was treated with an ACE inhibitor or an ARB had improved overall survival compared with patients who received other types of antihypertensive medications.9 In addition, many anti–VEGF-signaling pathway TKIs undergo metabolism by the cytochrome (CY) P450 3A4 isoenzyme; nondihydropyridine CCBs, such as verapamil and diltiazem, are inhibitors of CYP3A4 and therefore may not be preferred choices for the treatment of hypertension secondary to some anti–VEGF-signaling pathway TKIs. Furthermore, some regimens that include bevacizumab may include cytotoxic chemotherapy that is dependent on renal clearance, such as cisplatin and pemetrexed; therefore, caution with concomitant use of ACE inhibitors and ARBs should be exercised.12


VEGF-signaling pathway inhibitors is a common treatment modality for several types of cancer; therefore, hypertension secondary to such therapy can pose a challenge to clinicians. Hypertension should be managed to prevent additional and more severe complications, such as myocardial infarction or stroke. Antihypertensive therapy selection should be based on patient-specific factors, such as previous use of antihypertensive treatment, and the potential for drug interactions, adverse events of the antihypertensive drug, and comorbidities.

In some cases, anti–VEGF-signaling pathway therapy may require temporary discontinuation or dose reductions to manage the presence of severe, treatment-related hy­pertension, or hypertension refractory to medical management.

Author Disclosure Statement
Dr Moore, Dr Kientzel, and Ms Fasan have no conflicts of interest to report.


1. Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med. 2013;23:104-113.
2. An MM, Zou Z, Shen H, et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol. 2010;66:813-821.
3. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697-3705.
4. US Department of Health & Human Services. Common terminology criteria for adverse events (CTCAE). Version 4.03. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed October 25, 2017.
5. Chobanian AV, Bakris GL, Black HR, et al; for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; for the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560-2572. Erratum in: JAMA. 2003;290:197.
6. Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9:117-123.
7. Hamnvik OP, Choueiri TK, Turchin A, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121:311-319.
8. Kružliak P, Novák J, Novák M. Vascular endothelial growth factor inhibitor–induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. Am J Hypertens. 2014;27:3-13.
9. Izzedine H, Derosa L, Le Teuff G, et al. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol. 2015;26:1128-1133.
10. de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD. Management of antiangiogenic therapy-induced hypertension. Hypertension. 2012;60:607-615.
11. Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441-2447.
12. Maitland ML, Bakris GL, Black HR, et al; for the Cardiovascular Toxicities Panel. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102:596-604.
13. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520. Erratum in: JAMA. 2014;311:1809.
14. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20:807-815.

Related Items
A Taxing Consequence: Taxane Acute Pain Syndrome
Mark L. Zangardi, PharmD, BCOP
JHOP - June 2017 Vol 7, No 2 published on May 30, 2017 in Supportive Care, Symptom Management Overview
EGFR Inhibitor–Associated Papulopustular Rash
Donald C. Moore, PharmD, BCPS, BCOP
JHOP - March 2017 Vol 7, No 1 published on March 13, 2017 in Supportive Care
Last modified: January 16, 2018